Breaks Categories: News

MondayAug 28, 2017 9:15 am

CBDNewsBreaks – ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Announces Release of High Level CBD Product

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the release of one of Canada’s highest legal CBD:THC ratio products by wholly-owned subsidiary ABcann Medicinals Inc. CBD-Med has a ratio of 27.6:1 (18.5% CBD to 0.67% THC), making it one of Canada’s highest CBD products under Health Canada regulations. “The development of these products is in line with ABcann's corporate strategy as a premium product provider of organic, pesticide free cannabis,” Ken Clement, executive chairman of ABcann, stated in the news release. “As the Company continues to scale production capacity, our product line will expand as we strive to…

Continue Reading

ThursdayAug 24, 2017 9:18 am

CBDNewsBreaks – PotNetwork Holdings, Inc. (POTN) Subsidiary Achieves 30% Month-Over-Month Revenue Growth in July

PotNetwork Holdings, Inc. (OTC: POTN) this morning announced that its wholly owned subsidiary, Diamond CBD, Inc., has delivered a considerable month-over-month increase in revenues, recording $1,459,137 for the month of July. This total exceeded the company’s June revenues by more than 30 percent. “We are very pleased with how the numbers have continued to gain over the summer,” Maria Gomez, regional vice president of sales for Diamond CBD, Inc., stated in the news release. “We are consistently setting new sales records month after month and are excited to be able to report this type of continuing growth. We have taken…

Continue Reading

ThursdayAug 10, 2017 9:53 am

CBDNewsBreaks – Arcadia Biosciences, Inc. (NASDAQ: RKDA) and Bioceres’ Joint Venture Receives Completed Safety Review by FDA

Arcadia Biosciences (NASDAQ: RKDA) before the bell said its joint venture with Bioceres S.A., Verdeca, has received notification that the FDA has completed its full review of the company’s safety evaluation for HB4 soybeans. This permits Verdeca products derived from HB4 soybeans to be used commercially in human food and animal feed. Additionally, completion of the FDA’s review marks a key regulatory achievement in the approval process for Verdeca’s HB4 drought stress tolerance trait. The company has submitted an environmental safety data petition to the U.S. Department of Agriculture (USDA) which is currently under review. The USDA is expected to…

Continue Reading

ThursdayAug 10, 2017 9:49 am

CBDNewsBreaks – Data and Safety Monitoring Board Recommends Completion of ARCA biopharma, Inc.’s (NASDAQ: ABIO) GENETIC-AF Trial

ARCA biopharma (NASDAQ: ABIO) this morning said the GENETIC-AF trial Data and Safety Monitoring Board (DSMB) has completed its pre-specified phase 2B interim analysis and has recommended completion of the study with no changes to the trial design. GENETIC-AF is a clinical trial evaluating Gencaro™ as a candidate for the treatment of atrial fibrillation (AF). The Gencaro development program has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). “The DSMB stated that there were no safety concerns and that the efficacy results met the prespecified criteria for continuing the Phase 2B trial to completion. We…

Continue Reading

ThursdayAug 10, 2017 9:32 am

CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Discusses Company’s Progress in Interview

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced that its chief executive officer, Chris Bunka, was featured in a recent interview on the Uptick Network Stock Day Radio Show. Bunka leveraged the platform to discuss Lexaria’s overall accomplishments in the past three months, as well as the company’s expectations for profitability moving forward. He notes that ongoing research and development programs could open both the NSAID and Nicotine markets to Lexaria, providing an opportunity to significantly increase corporate revenues and facilitate further expansion. “In the…

Continue Reading

TuesdayAug 08, 2017 12:40 pm

CBDNewsBreaks – Rennova Health, Inc. (NASDAQ: RNVA) Opens Big South Fork Medical Center

Rennova Health (NASDAQ: RNVA) (NASDAQ: RNVAZ) this morning said it has opened the Big South Fork Medical Center (BSFMC) and provision of 24/7 services. Located in Oneida, Tennessee, the hospital offers in-patient and outpatient services including a 24/7 emergency department. Future plans for the hospital include submitting an application to be classified as a Critical Access Hospital which will in turn enable certain advantages with payers. "We believe our investment and ability to facilitate the needs of doctors and other healthcare providers in the local area will enable us to exceed previous revenues achieved by this hospital. This opening is…

Continue Reading

MondayAug 07, 2017 9:31 am

CBDNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Names Keevin Gillespie as Acting President of ChineseHempOil.com Subsidiary

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that it has appointed Keevin Gillespie as acting president of its wholly-owned ChineseHempOil.com, Inc. subsidiary, effective immediately. Per the update, Gillespie’s initial focus will be on promotion and branding of the company’s newly-launched ‘OptHemp’ health product line, which the company intends to market through several sales channels. He will also be spearheading the development of the company’s network marketing division. “I'm honored to serve as the President of ChineseHempOil.com, Inc.,” Gillespie stated in the news release. “As the many potential health benefits of hemp continue to be revealed through scientific…

Continue Reading

MondayAug 07, 2017 9:05 am

CBDNewsBreaks – SinglePoint, Inc. (SING) Provides First-Hand Look at Development of New Bitcoin Exchange

Specialized holding company SinglePoint, Inc. (OTC: SING) this morning offered a first-hand look at its new bitcoin exchange aimed at solving the payments issues plaguing today’s cannabis industry. When completed, the new in-house solution will enable consumers to obtain bitcoin at any point of sale. In addition to bitcoin, SinglePoint is currently in negotiations to make a major purchase from a company that offers a cannabis-specific cryptocurrency to be used specifically within the growing legal cannabis industry, which is on pace to reach $55.8 billion by 2025, per Grand View Research. “We are very excited about this solution,” Wil Ralston,…

Continue Reading

ThursdayAug 03, 2017 12:08 pm

CBDNewsBreaks – CHF Solutions, Inc. (NASDAQ: CHFS) Starts Aquadex FlexFlow® System Manufacturing Transition to its Minnesota Facility; Shares Rise

CHF Solutions, Inc. (NASDAQ: CHFS) shares surged 14% after the company this morning said it has commenced the process of transitioning the manufacturing of the Aquadex FlexFlow System from an indirect subsidiary of Baxter International, Inc. (NYSE: BAX) to CHF Solutions’ facility in Eden Prairie, Minnesota. Last week, the company completed the transfer of the manufacturing assets that it acquired from Baxter as part of the Aquadex acquisition that was completed on August 5, 2016. The company expects to begin manufacturing its Aquadex FlexFlow system products in the fourth quarter of 2017. “Bringing the manufacturing of the Aquadex FlexFlow system…

Continue Reading

ThursdayAug 03, 2017 12:05 pm

CBDNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Selects Bioscience SA as Polish CRO

Shares of Moleculin Biotech (NASDAQ: MBRX) rose 7% this morning on news that the company has selected Bioscience SA, a Polish contract research organization (CRO), to begin identifying and preparing clinical testing sites in Poland for Annamycin. The company’s drug candidate, Annamycin, is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia (AML). "One of the biggest challenges for most clinical trials is recruiting the right patients on a timely basis. We believe adding Polish sites to our planned trial introduces a significant population of qualified patients, and selecting Bioscience helps ensure we reach those patients effectively…

Continue Reading